HLA-A*03:01&B2M&gp100 (ALLAVGATK) Monomer, His & Avi, Human
HLA-A*03:01&B2M&gp100 (ALLAVGATK) Monomer, His & Avi, Human

The purity of HLA-A*03:01&B2M&gp100 (ALLAVGATK) Monomer, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

HLA-A*03:01&B2M&gp100 (ALLAVGATK) Monomer, His & Avi, Human

HLA-A*03:01&B2M&gp100 (ALLAVGATK) Monomer, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

HLA-A*03:01&B2M&gp100 (ALLAVGATK) Monomer, His & Avi, Human

Immunization against the ALLAVGATK peptide may occur in melanoma patients and that the immunogenicity of this peptide is similar to that of the majority of melanoma differentiation antigens defined to date. Therefore, the use of ALLAVGATK in active immunotherapy for HLA-A3 melanoma patients, for whom no other immunogenic peptide has been so far described, remains a distinct possibility, providing that patients treated in vivo with this peptide develop a better in vitro response than already demonstrated for HLA-A2 epitopes generated from this same antigenic protein.
Z06602
¥63,425.00

Ask us a question
Product Introduction
Species Human
Protein Construction
HLA-A*03:01&B2M&gp100 (ALLAVGATK) Monomer[Gly25-Thr305 (HLA-A*03:01), Ile21-Met119 (B2M) and ALLAVGATK peptide]
Accession # NP_002107.3(HLA-A*03:01)&P61769(B2M)&ALLAVGATK		 His Avi
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 50.15 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 51-60 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • HLA-A*03:01&B2M&gp100 (ALLAVGATK) Monomer, His & Avi, Human
    • HLA-A*03:01&B2M&gp100 (ALLAVGATK) Monomer, His & Avi, Human

    The purity of HLA-A*03:01&B2M&gp100 (ALLAVGATK) Monomer, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

  • HLA-A*03:01&B2M&gp100 (ALLAVGATK) Monomer, His & Avi, Human
    • HLA-A*03:01&B2M&gp100 (ALLAVGATK) Monomer, His & Avi, Human

    HLA-A*03:01&B2M&gp100 (ALLAVGATK) Monomer, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background Immunization against the ALLAVGATK peptide may occur in melanoma patients and that the immunogenicity of this peptide is similar to that of the majority of melanoma differentiation antigens defined to date. Therefore, the use of ALLAVGATK in active immunotherapy for HLA-A3 melanoma patients, for whom no other immunogenic peptide has been so far described, remains a distinct possibility, providing that patients treated in vivo with this peptide develop a better in vitro response than already demonstrated for HLA-A2 epitopes generated from this same antigenic protein.
Synonyms gp100 (ALLAVGATK)

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.